

PATENT/Docket No. PC9953D

Serial No. 10/601/209

Page 4

Response to 01/18/05 Office Action

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**LISTING OF CLAIMS**

1. (Currently amended) A compound of the formula




or the pharmaceutically acceptable salt thereof; wherein

Z is oxygen, S(O)<sub>m</sub> wherein m is 0, 1 or 2; or NQ wherein Q is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl;

X is hydrogen, chloro, fluoro, bromo, iodo, hydroxy, nitro, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkyl, trifluoromethyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl S(O)<sub>a</sub> wherein a is 0, 1 or 2; or phenyl wherein the phenyl group is optionally substituted by hydrogen, halo, hydroxy, nitro, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkyl, trifluoromethyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, or (C<sub>1</sub>-C<sub>6</sub>)alkyl S(O)<sub>b</sub> wherein b is 0, 1 or 2;

Y is



wherein M is oxygen or sulfur;

X<sup>2</sup> is hydrogen, fluoro, chloro, trifluoromethyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or (C<sub>1</sub>-C<sub>6</sub>)alkyl S(O)<sub>c</sub> wherein c is 0, 1 or 2;


R<sup>1</sup> is a group of the formulas

PATENT/Docket No. PC9953D

Serial No. 10/601/209

Page 5

Response to 01/18/05 Office Action



wherein the broken line represents an optional double bond;

p is [[1,] 2[[ or 3]];

E is oxygen or S(O)<sub>d</sub> wherein d is 0, 1 or 2;

R<sup>6</sup> is selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with (C<sub>1</sub>-C<sub>6</sub>)alkoxy or one to three fluorine atoms, or [(C<sub>1</sub>-C<sub>4</sub>)alkyl]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH<sub>2</sub>)<sub>q</sub>-, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and q is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, trifluoromethyl, cyano and (C<sub>1</sub>-C<sub>6</sub>)alkylS(O)<sub>e</sub>, wherein e is 0, 1 or 2;

R<sup>7</sup> is selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, [(C<sub>1</sub>-C<sub>4</sub>)alkyl]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH<sub>2</sub>)<sub>r</sub>-, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and r is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, trifluoromethyl, -C(=O)-(C<sub>1</sub>-C<sub>6</sub>)alkyl, cyano and (C<sub>1</sub>-C<sub>6</sub>)alkylS(O)<sub>f</sub>, wherein f is 0, 1 or 2; or R<sup>6</sup> and R<sup>7</sup> taken together form a 2 to 4 carbon chain;

R<sup>8</sup> is hydrogen or (C<sub>1</sub>-C<sub>3</sub>)alkyl;

R<sup>9</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

**PATENT**/Docket No. PC9953D

Serial No. 10/601/209

Page 6

Response to 01/18/05 Office Action

or  $R^6$  and  $R^9$ , together with the nitrogen atom to which they are attached, form a 5 to 7 membered heteroalkyl ring that may contain from zero to four heteroatoms selected from nitrogen, sulfur and oxygen;

$R^{10}$  is hydrogen or  $(C_1-C_6)$ alkyl;

$R^2$  is hydrogen,  $(C_1-C_4)$ alkyl, phenyl or naphthyl, wherein said phenyl or naphthyl may optionally be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, trifluoromethyl, cyano and  $(C_1-C_6)$ alkylS(O)<sub>g</sub> wherein g is 0, 1 or 2; and

$R^3$  is  $-(CH_2)_tB$ , wherein t is zero, one, two or three and B is hydrogen, phenyl, naphthyl or a 5 or 6 membered heteroaryl group containing from one to four heteroatoms in the ring, and wherein each of the foregoing phenyl, naphthyl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$  alkoxy- $(C_1-C_6)$ alkyl-, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, COOH and  $(C_1-C_6)$ alkylS(O)<sub>h</sub> wherein h is 0, 1 or 2.

2. (Original) A compound according to claim 1, wherein Z is oxygen, S(O)<sub>m</sub> wherein m is zero; or NH.

3. (Canceled).

4. (Original) A compound according to claim 1, wherein  $R^2$  is hydrogen or  $(C_1-C_4)$ alkyl and  $X^2$  is hydrogen, fluoro or chloro.

5. (Original) A compound according to claim 1, wherein  $R^3$  is  $-(CH_2)_tB$  wherein t is zero or one and B is phenyl or naphthyl wherein the phenyl and naphthyl groups may optionally be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$  alkoxy- $(C_1-C_6)$ alkyl-, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, COOH and  $(C_1-C_6)$ alkylS(O)<sub>h</sub> wherein h is 0, 1 or 2.

6. (Canceled).

7. (Canceled).

8. (Currently amended). A pharmaceutical composition for treating [[or preventing]] a disorder or condition selected from [[hypertension, depression,]] generalized anxiety disorder, [[phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation,

**PATENT**/Docket No. PC9953D

Serial No. 10/601/209

Page 7

Response to 01/18/05 Office Action

eating disorders, obesity, chemical dependencies, cluster headache,]] and migraine[[, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, cancer, chronic paroxysmal hemicrania and headache]] in a mammal, comprising an amount of a compound according to claim 1 that is effective in treating [[or preventing]] such disorder or condition and a pharmaceutically acceptable carrier.

9. (Canceled).

10. (Currently Amended). A method for treating [[or preventing]] a disorder or condition selected from [[hypertension, depression,]] generalized anxiety disorder, [[phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical dependencies, cluster headache,]] and migraine[[, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, cancer, chronic paroxysmal hemicrania and headache]] in a mammal, comprising administering to a mammal in need of such treatment [[or prevention]] an amount of a compound according to claim 1 that is effective in treating [[or preventing]] such disorder or condition.

11-24. (Canceled).